Effects of a Food for Special Medical Purposes containing D-Mannose, birch extract, vitamin D and vitamin A for the dietary management of acute symptomatic uncomplicated urinary tract infections in females - a randomized, double-blind, placebo-controlled, parallel-design study
- Conditions
- N39.0Urinary tract infection, site not specified
- Registration Number
- DRKS00013240
- Lead Sponsor
- Hermes Arzneimittel GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 95
Females susceptible to urinary tract infections with at least one acute uncomplicated UTI in the past 12 months or Females with acute UTI and history of acute uncomplicated UTI
BMI: =18 and =32 kg/m2 at screening
Nonsmoker and moderate smokers (max. 15 cigarettes/day)
Sum-score of the typical uUTI symptoms (dysuria, pollakisuria, urgency etc) reported on the Acute Cystitis Symptom Score (ACSS)-Typical domain at visit 1 is =6
Symptoms of the acute episode of lower uncomplicated UTI are developed within not more than 72 h prior to visit 1 (study entry)
Relevant history, presence of any severe medical disorder (heavy depression, diabetes, heavy liver disease, heavy cardiovascular diseases (e.g. stroke, heart attack), immunodeficiency (e.g. COPD), malignant tumor (including chemotherapy and radiation treatment))
Patient with central nervous system disease (e.g. Multiple sclerosis), and/or with mental status unable to coordinate
Any conditions that may lead to complicated infections (i.e., renal diseases, urinary tract abnor-malities (e.g. stone/mass) or past urinary surgery, urine catheterization, uncontrolled diabetes mellitus, spinal cord injury, etc.).
Known severe impaired renal function
Patients with overactive bladder
Planned gynecological surgery
Gastrointestinal diseases/conditions (colitis ulcerosa, Crohn’s IBS, peptic ulcers, celiac disease) that may significantly alter the absorption of study product
Chronic intake of medication/dietary supplements (e.g. cranberry, systemic cortisone) potential-ly interfering with this study during the last month before screening or during the study.
For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening
Participants anticipating a change in their lifestyle or physical activity levels during the study.
Subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study.
Known hypersensitivity to the study product or to single ingredients
Lactose intolerance
Pregnant subject or subject planning to become pregnant during the study; breast-feeding sub-ject.
Known HIV-infection
Known acute or chronic hepatitis B and C infection
Subject involved in any clinical or food study within the preceding month and during the study
Subjects considered inappropriate for the study by investigators, including patients who are un-able or unwilling to show compliance with the protocol
Presence of clinical signs and symptoms suggestive of pyelonephritis or complicated urinary tract infection (i.e., fever T =38.0°C, flank and/or back pain, chills and shivers), and/or vulvo-vaginitis with vaginal and/or with urethral discharge (without urination) at visit 1.
Any antibiotic therapy within 7 days prior to visit 1.
Other acute infections (except uncomplicated UTIs) requiring antibiotic treatment at visit 1.
Patients who took anti-inflammatory drugs (e.g., Ibuprofen) or spasmolytics for any reason within 12 hours prior to visit 1, and/or are not willing to stop the intake of any of the medication not permitted for use during the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method